Diamyd Medical announced today that sufficient amounts of GAD65, the active substance in the Diamyd® diabetes vaccine, for Phase III clinical trials have been produced at Protein Sciences, Meriden, CT, and sent for testing. Formulation and vialing is planned to take place in Europe in January 2008. The Company plans to file its IND with the US FDA in December. This means that approval to start the Phase III program can be granted during the 1st quarter 2008.
